Overall Survival Improving for Umbilical Cord Blood Transplant
By Elana Gotkine HealthDay Reporter
MONDAY, Oct. 7, 2024 -- For umbilical cord blood transplant (UCBT), overall survival has improved over time, according to a study published in the October issue of Transplantation and Cellular Therapy.
Karen Ballen, M.D., from the University of Virginia Health System in Charlottesville, and colleagues compared outcomes of UCBT by social determinants of health in a retrospective study. Data were included for U.S. patients aged 1 to 80 years: 983 received single and 1,529 received double UCBT following myeloablative or reduced-intensity conditioning for acute myeloid leukemia, acute lymphoid leukemia, or myelodysplasia.
The researchers found two-year overall survival was 41.5, 36.1, 45.8, and 44.5 percent for Whites, Latines, Blacks, and Asians, respectively, in a univariate analysis of 1,705 adults. Latine patients had inferior overall survival compared with Black patients in a multivariable analysis (hazard ratio, 1.45). For all racial/ethnic groups, overall survival improved over time. The different racial/ethnic groups had comparable graft-versus-host disease (GVHD) rates. In a univariate analysis of 807 children, two-year overall survival was 66.1, 57.1, 46.8, and 53.8 percent for Whites, Latines, Blacks, and Asians, respectively. No difference was seen in overall survival among racial/ethnic groups in a multivariable analysis. Grade III/IV acute GVHD was higher in Blacks than Whites and Latines (hazard ratios, 2.25 and 2.17, respectively).
"UCBT represents an important cell source for the diverse population of U.S. patients," the authors write. "We found that overall survival has improved over time, likely due to improvements in patient selection, human leukocyte antigen typing, and supportive care."
Several authors disclosed ties to the pharmaceutical and biotechnology industries.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
Leukemia Stem Cell-Based Method Aids Relapse Prediction in Acute Myeloid Leukemia
FRIDAY, Aug. 29, 2025 -- An assay that uses leukemia stem cells (LSCs) to assess measurable residual disease (MRD) outperforms traditional methods in patients with acute myeloid...
Mortality Up for Children With Leukemia From Lowest SES Neighborhoods
THURSDAY, Aug. 28, 2025 -- Children with acute lymphoblastic leukemia (ALL) from the lowest socioeconomic status (SES) neighborhoods have an increased risk for mortality...
Few With Myelodysplastic Syndromes Receive Hypomethylating Agents
MONDAY, Aug. 11, 2025 -- Few patients with myelodysplastic syndromes (MDS) receive treatment with hypomethylating agents (HMAs), with evidence of age-, sex-, and race-related...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.